Menu
News, Insights & Events
Many of the attorneys in the Law Firm Alliance author articles and thought leadership pieces on important topics and trends covering a wide variety of practices.
While these articles are correct on matters of law when they are produced, verdicts, rulings, legislation and other actions may affect the applicability of some of the information. Please consult your legal advisor before making decisions on the information you read here.
Articles
Ambulance Company Pays $65,000 Settlement
December 29, 2019
Danielle L. Dietrich, Esq.
View Article Details
The SECURE Act Finally is Enacted by Congress
December 29, 2019
View Article Details
“Quickie” Elections Are Not So “Quickie” Any More: NLRB Amends Union Representation Election Procedures
Labor and Employment
Subhash Viswanathan, Bond, Schoeneck & King
View Article Details
Hemp: The Legal Landscape Emerging Around the Production of Hemp and CBD Products
Environmental and Energy
Sarah M. Harvey, Bond, Schoeneck & King
View Article Details
2020 Pennsylvania Medical Record Fees
December 15, 2019
Michael A. Cassidy, Esq.
View Article Details
When Is My Disadvantaged Business Enterprise (DBE) No Longer Disadvantaged?
December 12, 2019
View Article Details
Losing Your Right to Appeal Through Silence
December 12, 2019
View Article Details
Telehealth Update: Connect for Health Act
December 10, 2019
View Article Details
Trade Secrets 101: If You Want To Call Something a Trade Secret, You Have To Take Steps To Protect It
December 9, 2019
View Article Details
2019 Amendments to the California Consumer Privacy Act Clarify Several Important Data Privacy Issues
Cybersecurity and Data Privacy
Robert W. Patterson and Jessica L. Copeland, Bond, Schoeneck & King
View Article Details
https://www.wardandsmith.com/articles/fda-issues-warnings-to-15-companies-for-illegally-selling-products-containing-cbd
November 26, 2019
Tyler Russell and Allen Trask,
Ward and Smith, P.A.
As made clear in prior FDA warning letters – and the 15 letters released on November 25th – there continues to be significant regulatory risk in the labeling and marketing of CBD products for sale in interstate commerce.
View Article Details